Overview

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Status:
Recruiting

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection & intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs. S1 plus oxaliplatin intravenous injection as first-line treatment in gastric or gastroesophageal junctional adenocarcinoma with malignant ascites.

Phase:

Phase 2

Details

Lead Sponsor:

China Medical University, China

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Oxaliplatin
Paclitaxel
Tegafur